U.S. Markets closed

Tesaro, Inc. (TSRO)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
149.11-4.08 (-2.66%)
At close: 4:00PM EDT
People also watch
CLVSKITEPBYIPTLAAGIO

Tesaro, Inc.

1000 Winter Street
Suite 3300
Waltham, MA 02451
United States
339-970-0900
http://www.tesarobio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees446

Key Executives

NameTitlePayExercisedAge
Mr. Leon O. Moulder Jr., M.B.A.Co-Founder, Chief Exec. Officer and Director1.09MN/A60
Dr. Mary Lynne Hedley Ph.D.Co-Founder, Pres, Chief Operating Officer and Director1.01MN/A54
Mr. Timothy R. PearsonChief Financial Officer and Exec. VP646.76kN/A49
Mr. Jeffrey H. Hanke Ph.D.Chief Scientific Officer and Exec. VP of R&D703.97k862.44k60
Dr. Martin H. Huber Jr., M.D.Chief Medical Officer and Sr. VP732.52kN/A57
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. The company is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in pre-clinical research stage targeting lymphocyte-activation gene-3. It has license and collaboration agreements with AnaptysBio, Inc.; and The University of Texas MD Anderson Cancer Center, as well as with Janssen Biotech, Inc., Zai Lab (Shanghai) Co., Ltd, and OPKO Health, Inc. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Tesaro, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.